Compare Amgen, Inc. (AMGN) vs Wipro Limited (WIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Wipro Limited — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Wipro Limited trades at $1.89 (market cap $18.38B). The key difference: Amgen, Inc. is far larger — about 10.7× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (10.25%). Which is the better fit depends on your goals.
| AMGN | WIT | |
|---|---|---|
Market Cap | $196.12B | $18.38B |
Sector | Health | Technology |
52-Week High | $388.16 | $3.06 |
52-Week Low | $271.18 | $1.82 |
Enterprise Value | $241.41B | $14.77B |
Dividend Yield | 2.77% | 10.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
WIT trades at $1.87, up 1.08% today, but faces bearish technical signals with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. Fundamentals show solid profitability with a 14.25% net margin and 15.4% ROE, while valuation metrics like a P/E of 14.05 appear reasonable. Recent news highlights AI partnerships with ServiceNow and Anthropic, though weak Q2 2026 guidance has pressured sentiment.
The outlook is cautious with mixed analyst ratings (19% buy, 48% hold, 33% sell) and near-term revenue headwinds. Investment opportunities lie in AI-driven growth initiatives, but risks include execution challenges and competitive pressures in the IT services sector. Cash flow remains strong at $25.02B net for 2025, supporting financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
